Its launch price has been set at $650 per 100 mg vial and $3,250 per 500 mg vial ... a renaissance for its cancer business along with Libtayo (cemiplimab), a PD-1 inhibitor that was sixth to ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Libtayo shows robust growth in specific cancers, although it faces stiff competition in broader indications, highlighting Regeneron’s ability to develop blockbuster drugs. Regeneron appears ...